Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Jaguar Health (JAGX) EBITDA Margin (2016 - 2025)

Jaguar Health (JAGX) has disclosed EBITDA Margin for 11 consecutive years, with 656.63% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 42417.0% to 656.63% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 398.82% through Dec 2025, down 13506.0% year-over-year, with the annual reading at 398.82% for FY2025, 13506.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 656.63% at Jaguar Health, down from 234.77% in the prior quarter.
  • The five-year high for EBITDA Margin was 54.39% in Q4 2022, with the low at 58770.0% in Q1 2022.
  • Average EBITDA Margin over 5 years is 5064.68%, with a median of 339.0% recorded in 2023.
  • The sharpest move saw EBITDA Margin plummeted -3220636bps in 2022, then surged 5825910bps in 2023.
  • Over 5 years, EBITDA Margin stood at 506.89% in 2021, then skyrocketed by 89bps to 54.39% in 2022, then crashed by -504bps to 328.57% in 2023, then grew by 29bps to 232.46% in 2024, then plummeted by -182bps to 656.63% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 656.63%, 234.77%, and 268.78% for Q4 2025, Q3 2025, and Q2 2025 respectively.